Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03917082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Study acronym: LALEAST
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 15, 2023 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 1, 2019 to Sep 23, 2019 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date changed from estimate of May 1, 2019 to Sep 23, 2019
    • Study sites: 0 to 1
  3. Eligibility criteria expanded, about 32 words Secondary endpoints: details revised at 2 of 2 entries · Study description expanded, about 3 wordsv2 Show 2 more changesShow less
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk of breast cancer; as determined by histopathologic criteria and confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this population, and will not compromise the expected excellent breast cancer specific outcomes for this population.
Trial Details
NCT Number NCT03917082
Lead Sponsor British Columbia Cancer Agency
Collaborators: Canadian Cancer Society (CCS), NanoString Technologies, Inc.
Conditions Breast Cancer Female, Hormone Receptor Positive Tumor
Enrollment 290 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov